Your browser does not support iframes.
First and Only Breath-Actuated Aerosol Inhaled Corticosteroid in the
United States Designed to Help Eliminate the Need for Hand-Breath
JERUSALEM--(BUSINESS WIRE)--Feb. 16, 2018--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced
today that QVAR® RediHaler™ (beclomethasone
dipropionate HFA) Inhalation Aerosol is now commercially available to
patients in both 40 mcg and 80 mcg strengths by prescription in the U.S.
QVAR® RediHaler™ is the first and only
breath-actuated aerosol inhaled corticosteroid for the maintenance
treatment of asthma as a prophylactic therapy in patients 4 years of age
and older. It is not indicated for the relief of acute bronchospasm.
This press release features multimedia. View the full release here:
QVAR® RediHaler™ product image (Photo: Business Wire)
“When it comes to the treatment of asthma, proper inhaler technique
remains a critical issue for patients. In fact, nearly 68 percent of
patients do not use their metered dose inhalers (MDIs) well enough to
benefit from the prescribed medication1, leading to
potentially uncontrolled asthma symptoms2,” said Dr. Warner
W. Carr, MD, Associate Medical Director of Southern California Research
at Allergy and Asthma Associates of Southern California Medical Group.
“As a physician, it’s often a challenge to know if my patients are using
their inhalers correctly once they leave the office. It’s reassuring to
see new device technologies come to market, such as the QVAR®
RediHaler™ device, which is designed specifically to
eliminate the need for hand-breath coordination.”
QVAR® RediHaler™ differs from conventional
metered-dose inhalers (MDIs) as it delivers medication via a
breath-actuated inhaler, eliminating the need for hand-breath
coordination during inhalation. QVAR® RediHaler™
administers the same active ingredient found in the previously available
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol,
but utilizes innovative breath-actuated inhaler technology. QVAR® RediHaler™
was also designed to be ready for use, with no shaking or priming
needed. Because the medication delivery is breath actuated, it should
not be used with a spacer or volume holding chamber.
“QVAR® has been an available asthma treatment option for well
over a decade, so we are excited by the new technology of QVAR®
RediHaler™ that directly addresses an unmet need in the field
of asthma management,” said Brendan O’Grady, Executive Vice President,
North America Commercial at Teva. “By merging our breath-actuated
inhaler technology with asthma medication, we hope to better serve the
needs of the respiratory community and look forward to seeing the
adoption of QVAR® RediHaler™ in the coming months.”
With the launch of QVAR® RediHaler™, Teva is discontinuing
sales of the previously available QVAR®. Patients currently
prescribed QVAR® and/or their caregivers are encouraged to
speak with a healthcare professional about how this new treatment option
may impact their treatment plan and how to obtain and use QVAR®
RediHaler™, if desired. QVAR® RediHaler™
will be priced at parity to QVAR®.
QVAR® RediHaler™ (beclomethasone dipropionate HFA) Inhalation
Aerosol is a breath-actuated inhaled prescription medicine used as a
maintenance treatment for the prevention and control of asthma in people
4 years of age and older.
QVAR® RediHaler™ Inhalation Aerosol is not used to
relieve sudden breathing problems and won’t replace a rescue inhaler.
Important Safety Information
Please see full Prescribing Information at http://www.qvarredihaler.com/Pdf/PI.pdf
A copy may be requested from the US Medical Information Contact Center
for Teva Specialty Medicines at 888-4-TEVA-RX (888-483-8279) and USMedInfo@tevapharm.com
or Teva’s Public Relations or Investor Relations contacts.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva's net
revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding the U.S. launch of QVAR® RediHaler™,
which are based on management’s current beliefs and expectations and are
subject to substantial risks and uncertainties, both known and unknown,
that could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to:
1. Fink JB, Rubin BK. Problems with inhaler use: a call for improved
clinician and patient education. Respir Care. 2005;50(10):1360-1374.2.
D. Price, S. Bosnic-Anticevich, A. Briggs, H. Chrystyn, C. Rand, G.
Scheuch, J. Bousquet. Inhaler competence in asthma:Common errors,
barriers to use and recommended solutions. Respiratory Medicine. 2013;
View source version on businesswire.com: http://www.businesswire.com/news/home/20180212005322/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.IR Contacts:United StatesKevin
C. Mannix, 215- 591-8912Ran Meir, 215-591-3033orIsraelTomer
Amitai, 972 (3) 926-7656orPR Contacts:IsraelYonatan
Beker, 972 (54) 888-5898orUnited StatesKaelan
Hollon, 202-412-7076Michelle Larkin, 610-786-7335